7042 Background: In recent years, bispecific T cell Engagers (BsTCE) targeting CD3 and CD20 have emerged as a potent new class of therapeutics for NHL; however, a subset of patients still experience relapsed or refractory disease. Patients undergoing treatment with BsTCEs could benefit from longitudinal screening via liquid biopsy to identify baseline (primary) and treatment-induced (acquired) resistance mutations and tailor treatment accordingly. Here we present the results from a pilot study screening patients treated with Glofitamab (CD20xCD3) using a single gene Primer Extension Target Enrichment (PETE) strategy for MS4A1 (CD20 gene) in liquid biopsies. Methods: Our pilot study was conducted using libraries from the plasma of 134/155 patients with relapsed or refractory large B cell lymphoma (r/r LBCL) who underwent Glofitamab treatment at approved dose in the phase I/II trial NP30179 ( NCT03075696 ) (Dickinson, et al. N Engl J Med 2022), and paired PBMC/PDB available in 91 cases. Primers were designed against the coding regions of the MS4A1 gene. Enrichment was performed using a workflow optimized for the detection of somatic variants in cell-free DNA isolated from plasma. Results were analyzed using a modified AVENIO circulating tumor (ct) DNA (Roche; For Research Use Only) analysis workflow. Variants detected by the analysis pipeline were further filtered based on inclusion criteria: allele fraction > 0.1%, rarity in the cohort, impact on protein function in silico , and if sample was available, absence in germline. Tumor burden as assessed by ctDNA was obtained from retrospective sequencing data. Response to treatment was assessed by PET/CT using the Lugano Criteria. Results: Using inclusion criteria a total of 11/134 (8.2%) patients were identified with a total of 16 unique MS4A1 candidate mutations at baseline or during treatment. The Best Overall Investigator Response (BOR) was progressive disease (PD) for 7 patients and partial metabolic response (PR) for 4 patients. All patients with BOR PR experienced disease progression before treatment completion. Sufficient samples were available to demonstrate expansion of the candidate mutation by the end of treatment (EOT) timepoint for 5 patients. Four of the identified mutations were previously reported in the literature, the remaining mutations were novel, and in vitro characterization demonstrated their functional impact. Conclusions: This work identifies known and novel mutations in CD20 in plasma samples as a potential contributing mechanism to relapsed or refractory cases of NHL. Although the prevalence appears to be low, this is consistent with previous reports and supports investigation of the clinical utility, including utility as a potential predictive biomarker, of sequencing this gene during treatment with CD20xCD3 BsTCE. Future and ongoing work will screen additional cohorts and therapy combinations.
Geospatial intelligence is a subject with many opportunities for machine automation. Object detection is one desirable application. However, a lack of high-volume relevant datasets can make this task difficult. To combat this issue, we introduced a spin-set augmentation technique to generate synthetic training data. We used these synthetic datasets to augment the training of an object detection deep network, focusing on visible band imagery. We have continued our efforts by further testing this method on long-wave infrared imagery, including results from YOLO, SSD, and Faster R-CNN algorithms. We also introduce another synthetic augmentation technique which involves generating physics-based fully-rendered images of 3D synthetic scenery and targets and compared the rendered image performance to that of spin-sets. This paper analyzes both the spin-set and rendered image augmentation techniques in terms of object detection performance, complexity, generalizability, and explainability.
Increased adoption of personalized medicine has brought comprehensive genomic profiling (CGP) to the forefront. However, differences in assay, bioinformatics, and reporting systems and lack of understanding of their complex interplay are a challenge for implementation and achieving uniformity in CGP testing. Two commercially available, tissue-based, in-house CGP assays were compared, in combination with a tertiary analysis solution in a research-use only (RUO) context: the AVENIO Tumor Tissue CGP RUO Kit paired with navify Mutation Profiler (RUO) software and the TruSight Oncology 500 RUO assay paired with PierianDx Clinical Genomics Workspace software. Agreements and differences between the assays were assessed for short variants, copy number alterations, rearrangements, tumor mutational burden, and microsatellite instability, including variant categorization and clinical trial-matching (CTM) recommendations. Results showed good overall agreement for short variant, known gene fusion, and microsatellite instability detection. Important differences were obtained in tumor mutational burden scoring, copy number alteration detection, and CTM. Differences in variant and biomarker detection could be explained by bioinformatic approaches to variant calling, filtering, tiering, and normalization; differences in CTM, by underlying reported variants and conceptual differences in system parameters. Thus, distinctions between different approaches may lead to inconsistent results. Complexities in calling, filtering, and interpreting variants illustrate key considerations for implementation of any high-quality CGP in the laboratory and bringing uniformity to genomic insight results.
The investigation focused on effect of family relation on self - actualization of physically handicapped adolescent boys and girls. 240 boys and girls selected on the basis of family relation through multistage sampling in each group are compared through analysis of variance. Significant effect of parent child relation & personality variables is noted.
BACKGROUND-AIMStatins, a class of lipid lowering medications are the keystone treatment in the primary and secondary prevention of cardiovascular disease.Nevertheless they show a significant inter-individual variability in terms of efficacy and safety.This variability is related to various factors including genetic factors.We are interested in studying eight polymophisms.